CONGRESS ABSTRACT

Background: In the 3-year SURMOUNT-1 study, this post hoc analysis assessed changes in cardiometabolic risk factors based on body weight reduction thresholds with tirzepatide. Methods: Participants (N=458) randomized to receive tirzepatide (pooled 5/10/15 mg doses) and with an on-treatment body weight measurement at Week 176 were included in the…

Background Objective: deliver a 12-month, harmonized comparison of Semaglutide and Tirzepatide across three shared clinical domains: weight reduction, glycemic improvement, and cardiovascular risk reduction. Because individual patient data from original trials are not available, a synthetic cohort and propensity-score matching framework were used to approximate balanced treatment groups. Methods…

Background Type 2 diabetes mellitus (T2DM) is a major health issue worldwide due to its increasing prevalence and strong association with cardiovascular morbidity and mortality. Chronic hyperglycemia and insulin resistance cause endothelial dysfunction, vascular inflammation, and accelerated atherosclerosis. In T2DM patients, plaques tend to have higher lipid content, increased…

Background Patients with diabetes mellitus represent a heterogeneous population with a wide range of cardiovascular (CV) risk, from primary prevention to advanced atherosclerotic cardiovascular disease (ASCVD). Despite increasing evidence supporting integrated cardio-diabetology models, real-world data on the longitudinal impact of structured care pathways on patient profiling and risk factor…

Diabetes mellitus increases the risk of atherosclerotic cardiovascular disease (ASCVD). Diabetic patients often present with diffuse, calcified, and multivessel disease, complicating diagnosis and revascularization strategies. Critical stenoses of the left anterior descending (LAD) artery and left main coronary artery (LM) are associated with poor prognosis. Peripheral arterial disease (PAD),…

Introduction: This post-hoc analysis evaluated the proportion of participants with obesity and prediabetes who met the combined goal of weight reduction >5%, systolic blood pressure (SBP) reduction >5 mmHg and non-HDL cholesterol reduction >10% from baseline to Week 176 in SURMOUNT-1 3-year trial. Methods: Post-hoc analyses included participants with…